These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6661730)

  • 21. Effects of scopolamine (0.25-0.75 mg i.m.) on the quantitative EEG and the neuropsychological status of healthy volunteers.
    Sannita WG; Maggi L; Rosadini G
    Neuropsychobiology; 1987; 17(4):199-205. PubMed ID: 3441275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
    Richter N; Beckers N; Onur OA; Dietlein M; Tittgemeyer M; Kracht L; Neumaier B; Fink GR; Kukolja J
    Brain; 2018 Mar; 141(3):903-915. PubMed ID: 29309600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women.
    Dumas J; Hancur-Bucci C; Naylor M; Sites C; Newhouse P
    Neuropsychopharmacology; 2006 Sep; 31(9):2065-78. PubMed ID: 16482084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholinergic 'blockade' as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome.
    Kopelman MD; Corn TH
    Brain; 1988 Oct; 111 ( Pt 5)():1079-110. PubMed ID: 3179685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible biochemical basis of memory disorder in Alzheimer disease.
    Smith CM; Swash M
    Ann Neurol; 1978 Jun; 3(6):471-3. PubMed ID: 209723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of physostigmine and lecithin on memory in Alzheimer disease.
    Peters BH; Levin HS
    Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No response to high-dose muscarinic agonist therapy in Alzheimer's disease.
    Mouradian MM; Mohr E; Williams JA; Chase TN
    Neurology; 1988 Apr; 38(4):606-8. PubMed ID: 3281057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.
    Beller SA; Overall JE; Swann AC
    Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of scopolamine on visual evoked potentials in aging and dementia.
    Ray PG; Meador KJ; Loring DW; Murro AM; Buccafusco JJ; Yang XH; Zamrini EY; Thompson WO; Thompson EE
    Electroencephalogr Clin Neurophysiol; 1991; 80(5):347-51. PubMed ID: 1716558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alzheimer's disease and senile dementia of Alzheimer type. A neuropsychological study.
    Sulkava R; Amberla K
    Acta Neurol Scand; 1982 Jun; 65(6):651-60. PubMed ID: 7113669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills.
    Duka T; Ott H; Rohloff A; Voet B
    Psychopharmacology (Berl); 1996 Feb; 123(4):361-73. PubMed ID: 8867876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholinergic function and intellectual decline in Alzheimer's disease.
    Collerton D
    Neuroscience; 1986 Sep; 19(1):1-28. PubMed ID: 3537837
    [No Abstract]   [Full Text] [Related]  

  • 33. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86.
    Bruno G; Mohr E; Gillespie M; Fedio P; Chase TN
    Arch Neurol; 1986 Jul; 43(7):659-61. PubMed ID: 3524514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alzheimer's disease and senile dementia of Alzheimer type. A comparative study.
    Sulkava R
    Acta Neurol Scand; 1982 Jun; 65(6):636-50. PubMed ID: 7113668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging.
    Araujo JA; Studzinski CM; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):411-22. PubMed ID: 15795050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Failure of single-dose lecithin to alter aspects of central cholinergic activity in Alzheimer's disease.
    Pomara N; Domino EF; Yoon H; Brinkman S; Tamminga CA; Gershon S
    J Clin Psychiatry; 1983 Aug; 44(8):293-5. PubMed ID: 6874650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
    Brassen S; Adler G
    Pharmacopsychiatry; 2003 Nov; 36(6):304-8. PubMed ID: 14663655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease.
    Muramoto O; Sugishita M; Ando K
    J Neurol Neurosurg Psychiatry; 1984 May; 47(5):485-91. PubMed ID: 6736979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple-dose arecoline infusions in Alzheimer's disease.
    Tariot PN; Cohen RM; Welkowitz JA; Sunderland T; Newhouse PA; Murphy DL; Weingartner H
    Arch Gen Psychiatry; 1988 Oct; 45(10):901-5. PubMed ID: 3048224
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.